<DOC>
	<DOCNO>NCT00828386</DOCNO>
	<brief_summary>This randomize , multicenter , phase III trial compare induction chemotherapy Docetaxel , Cisplatin 5-Fluorouracil ( TPF ) follow concurrent chemoradiotherapy concurrent chemoradiotherapy alone , nasopharyngeal cancer stag T2b , T3 , T4 and/or lymph node involvement ( ≥ N1 . The main end point event free survival .</brief_summary>
	<brief_title>Induction Chemotherapy Chemoradiotherapy Nasopharyngeal Cancers</brief_title>
	<detailed_description>This randomize , multicenter , phase III trial compare induction chemotherapy Docetaxel , Cisplatin 5-Fluorouracil ( TPF ) follow concurrent chemoradiotherapy ( Arm A ) concurrent chemoradiotherapy alone ( Arm B ) , nasopharyngeal cancer stag T2b , T3 , T4 and/or lymph node involvement ( ≥ N1 . The main end point event free survival . The treatment : Arm A : induction chemotherapy : Docetaxel ( 75 mg/m² administer D1 course , every 3 week via one-hour IV infusion ) + Cisplatin ( 75 mg/m² administer D1 via one-hour infusion ) + 5-FU ( 750 mg/m²/d administer continuous infusion D1 D5 . The cycle repeat every 3 week total 3 course . follow chemoradiotherapy Cisplatin ( 40 mg/m2 start D1 radiation therapy ) 7 week Arm B : Chemoradiotherapy Cisplatin alone ( 40 mg/m2 start D1 radiation therapy ) 7 week</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1. WHO IIIII carcinoma nasopharynx , histologically proven nasal cavity biopsy , locally advanced T2b , T3 , T4 and/or N1 , N2 N3 ( UICC/AJCC2002 ) . 2 . Absence distant metastasis , confirm chest CT scan , abdominal ultrasound ( CT scan ) case abnormal hepatic function , bone scintigraphy require . 3 . Total absence previous chemotherapy radiotherapy , whatever reason . 4 . Total absence surgical procedure nasopharyngeal carcinoma . 5 . Total absence concurrent cancer treatment . 6 . Total absence chronic treatment ( &gt; = 3 month ) corticosteroid daily dosage &gt; = 20 mg/day methylprednisolone equivalent . 7 . Age 18 70 year . 8 . Performance status 0 1 accord WHO criterion . 9 . Hematological function parameter perform within 10 day inclusion : Neutrophils &gt; = 1.5 * 109/l Platelets : &gt; = 100 * 109/l Hemoglobin : &gt; = 10 g/dl 10 . Hepatic function parameter perform within 10 day inclusion : Total bilirubin normal AST ( SGOT ) ALT ( SGPT ) &lt; = 2.5 * upper limit normal ( ULN ) center . Alkaline phosphatase &lt; = 2.5 * ULN . 11 . Renal function parameter perform within 10 day inclusion : Creatinine clearance must &lt; = 55 ml/min . 12 . Patient give his/her write consent specific procedure protocol . 13 . Patient Social Security ( social policyholder ) 1. WHO I carcinoma nasopharynx , histologically proven nasal cavity biopsy . 2 . Other previous concomitant cancer , except situ cervical cancer cutaneous basal cell carcinoma . 3 . Histological diagnosis lymph node biopsy . 4 . Pregnant breastfeeding female , female male childbearing potential take adequate contraceptive measure . 5 . Symptomatic peripheral neuropathy grade &gt; = 2 accord NCICTC criterion . 6 . Other serious concurrent medical disease ( nonexhaustive list ) : Unstable heart disease despite treatment . Myocardial infarction within 6 month inclusion trial . A history neurological psychiatric event dementia , convulsion . Severe uncontrolled infection . Active gastroduodenal ulcer . Obstructive Pulmonary Disease require hospitalization within year prior inclusion . 7 . Clinical impairment auditory function . 8 . The presence , time screening , psychological , familial , social geographical factor may effect compliance patient study protocol monitoring comprises exclusion criterion . These factor must discuss patient inclusion trial . 9 . Hypersensitivity excipients . 10 . A patient already enrol another therapeutic trial investigational compound . 11 . A person deprive liberty care guardian .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Nasopharyngeal cancer</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>radiochemotherapy</keyword>
</DOC>